NASD · Healthcare · Biotechnology · United Kingdom
Roivant Sciences Ltd is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Roivant Sciences is a biopharmaceutical company developing medicines through a network of subsidiary companies called Vants. Its pipeline includes brepocitinib for dermatomyositis and other autoimmune conditions, IMVT-1402 for IgG-mediated autoimmune diseases, and mosliciguat for pulmonary hypertension. The company additionally invests in early-stage discovery ventures and health technology businesses.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Roivant Sciences Ltd stock.
Overvalued: intrinsic value $6.58 per share, market price $34.70, margin of safety -427.6% (as of 2026-10-19).
Its liquidation floor, current assets minus every liability, values the shares at $6.58; the price of $34.70 is 428% above that value.
17 more funds hold it; the full list is part of the paid plan.
92 more in this industry show a wider margin of safety.
ROIV is overvalued (as of the 2026-10-19 close). Its liquidation floor, current assets minus every liability, values the shares at $6.58; the price of $34.70 is 428% above that value.
$6.58 per share (as of the 2026-10-19 close), against a market price of $34.70. That is a margin of safety of -427.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.